Andrew Porter, PA
Physician Assistant · Mesa, AZNPI 1801826094
Payments from drug & device makers
Across 228 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$547
- Amgen$443
- Novo Nordisk$382
- GSK$330
- Pfizer$268
- Bayer$267
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,096100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $547 |
| Amgen | 31 | $443 |
| Novo Nordisk | 25 | $382 |
| GSK | 16 | $330 |
| Pfizer | 15 | $268 |
| Bayer | 12 | $267 |
| Abbott | 10 | $225 |
| AstraZeneca | 6 | $212 |
| Lilly USA, LLC | 10 | $195 |
| Exact Sciences | 7 | $154 |
| Sumitomo Pharma America, Inc. | 6 | $146 |
| Boehringer Ingelheim | 4 | $86 |
| Merck | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $68 |
| Dexcom, Inc. | 3 | $68 |
| Medtronic | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Insulet Corporation | 3 | $53 |
| Astellas Pharma US Inc | 2 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Inspire Medical Systems, Inc. | 2 | $33 |
| Seqirus USA Inc | 2 | $30 |
| Novartis | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Gilead | 1 | $15 |
| Incyte Corporation | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,096 in reported general payments places this provider in the 85th percentile of 2,888 physician assistant providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Soliqua 100-33Insulin Glargine/Lixisenatide | 105 | $86,851 |
| JardianceEmpagliflozin | 62 | $73,309 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 45 | $40,750 |
| EliquisApixaban | 27 | $34,931 |
| OzempicSemaglutide | 31 | $29,654 |
| FarxigaDapagliflozin Propanediol | 26 | $26,435 |
| JanuviaSitagliptin Phosphate | 16 | $25,108 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $20,841 |
| LinzessLinaclotide | 19 | $18,966 |
| MounjaroTirzepatide | 15 | $15,986 |
| MyrbetriqMirabegron | 23 | $14,847 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,046 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $4,931 |
| Valsartan | 52 | $2,853 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Glyxambi | $86 | $134,900121 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $44 | $86,851105 claims |
| PfizerEliquis | $268 | $34,93127 claims |
| Novo NordiskOzempic | $382 | $29,65431 claims |
| AstraZenecaFarxiga | $212 | $26,43526 claims |
| MerckJanuvia | $75 | $25,10816 claims |
| AbbVieLinzess | $547 | $18,96619 claims |
| Lilly USA, LLCMounjaro | $195 | $15,98615 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $14,84723 claims |
| GSKTrelegy Ellipta | $330 | $7,04611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,888 physician assistant providers in Arizona.
Other physician assistant in Mesa
- Jessica RosenblumMesa$19K
- Katrina McDanielMesa$14K
- Jenna HiltonGilbert$637K
- Kara GoodingScottsdale$625K
- Ginna GranrothScottsdale$211K
- Nicole MaderaGlendale$128K
- Candace RyanGlendale$113K
- Alyssa BoschenPhoenix$86K
- Christopher BeroScottsdale$81K
- Katherine MinorPhoenix$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.